This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Tempus Labs, Inc.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: The Innovations of Benjamin Leibowitz
Introduction
Benjamin Leibowitz is an accomplished inventor based in Chicago, IL. He has made significant contributions to the field of cancer research through his innovative patent. His work focuses on improving the understanding and treatment of cancers with homologous recombination pathway deficiencies.
Latest Patents
Leibowitz holds a patent for "Systems and methods for predicting homologous recombination deficiency status of a specimen." This patent involves methods, systems, and software designed for an ensemble model that distinguishes between cancers with homologous recombination pathway deficiencies (HRD positive cancers) and those without (HRD negative cancers). The model utilizes nucleic acid sequencing data, including both RNA and DNA sequencing data, derived from cancerous tissue samples.
Career Highlights
Throughout his career, Benjamin Leibowitz has worked with notable companies such as Tempus Labs, Inc. and Tempus AI, Inc. His expertise in cancer genomics has positioned him as a valuable asset in the research community.
Collaborations
Leibowitz has collaborated with esteemed colleagues, including Joshua S. K. Bell and Catherine Igartua, contributing to advancements in cancer research and treatment methodologies.
Conclusion
Benjamin Leibowitz's innovative work and patent in cancer research highlight his commitment to improving patient outcomes. His contributions continue to influence the field and pave the way for future advancements in cancer treatment.